Dergiler / Turkish Journal of Gastroenterology / 2014 / Cilt: 25 - Sayı: 3

Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases

Sayfa
253–256
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

However, to test the validation, a larger number samples is required.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein with vital function during human embryogenesis in terms of cellular growth and migration.
📊
Temel Bulgular & Veri:Few studies have recommend application of IMP3 expression to diagnose challenging cases of esophageal adenocarcinoma.
💡
Sonuç & Katkı:However, to test the validation, a larger number samples is required.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein with vital function during human embryogenesis in terms of cellular growth and migration. Although it has minimum and undetectable expression in human adult tissues, it is highly expressed in various types of cancer. Few studies have recommend application of IMP3 expression to diagnose challenging cases of esophageal adenocarcinoma. This survey was aimed to evaluate the benefit of IMP3 expression detection in the diagnosis of esophageal adenocarcinoma and high-grade dysplasia by using immunohistochemistry (IHC).Materials and Methods: An immunohistochemistry study of IMP3 oncofetal protein was performed on paraffinembedded blocks of 76 cases, including Barrett's esophagus, esophageal squamous epithelium, Barrett's esophagus with low-grade dysplasia, Barrett's esophagus with high-grade dysplasia, moderately differentiated esophageal adenocarcinoma, and poorly differentiated esophageal adenocarcinoma. Two pathologists reevaluated the diagnosis and evaluated the positivity and intensity of the IHC staining as well.Results: Insulin-like growth factor II mRNA-binding protein 3 expression was intensely positive in all cases of esophageal adenocarcinoma and Barrett's esophagus with HGD. Only mild positivity in 30% of Barrett's esophagus with LGD was seen. However, Barrett's esophagus and esophageal squamous epithelium had, in fact, no IMP3 expression.Conclusion: The percentage and intensity of IP3 IHC staining showed a significant difference between highgrade dysplasia and adenocarcinoma versus Barrett's esophagus with low-grade dysplasia, Barrett's esophagus, and esophageal squamous epithelium. Therefore, IMP3 oncofetal protein could be a very useful marker for the diagnosis of high-grade dysplasia and adenocarcinoma. However, to test the validation, a larger number samples is required.

🔖

Bu Makaleye Atıf Yap

KAZEMİNEZHAD, B., MİRAFSHARİEH, S. A., DİNYARİ, K., AZİZİ, D., EBRAHİMİ, A. (2014). Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases. Turkish Journal of Gastroenterology, Cilt: 25 - Sayı: 3, 253–256. https://ajindex.com/articles/411329

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241-52. [CrossRef] Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.Hum Pathol 2001; 32: 368-78. [CrossRef] Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predic- tive marker for invasive carcinoma in Barrett's esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001; 32: 379-88. [CrossRef] Rice TW, Falk GW, Achkar E, et al. Surgical management of highgrade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993; 88: 1832-6.
  2. Lu, D., Poon am Vohra, Peigou G. Chu, et al. An oncofetal protein IMP3: A new molecular marker for the detection of esophageal adenocar- cinoma and high-grade dysplasia. Am J Surg Pathol 2009; 33: 521-5. [CrossRef] Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a trans- lational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517-24. [CrossRef] Vikesaa J, Hansen TV, Jonson L, et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-68. [CrossRef] Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly con- served RNA binding protein KOC in embryogenesis. Mech Dev 1999; 88: 95-9. [CrossRef] Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-70.
  3. Nielsen FC, Nielsen J, Christiansen J. A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest 2001; 61: 93-9. [CrossRef] Li C, Rock KL, Woda BA, et al. IMP3 is a novel biomarker for adeno- carcinoma in situ of the uterine cervix: an immunohistochemi- cal study in comparison with p16(INK4a) expression. Mod Pathol 2007; 20: 242-7. [CrossRef] Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997; 14: 2729-33. [CrossRef] Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003; 88: 887- 94. [CrossRef] Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain con- taining protein overexpressed in cancer): A novel molecular marker that distinguishes between benign and malignant lesion